

References

S-212

1. Haverman T, Durlacher J, Rademacher W, et al. Oral complications in hematopoietic stem cell recipients: The role of inflammation. *Mediators of Inflammation*. 2014;378281.
2. Peinemann F, Smith L, Kromp M, et al. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: A Cochrane systematic review. *BMJ Open*. 2014;4:e005033.
3. National Cancer Institute (NCI). Stem Cell Transplant. April 29, 2015. Accessed September 16, 2015.
4. American Cancer Society. Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants) October 2, 2013. Accessed September 16, 2015.
5. Atsuta Y, Suzuki R, Yamashita T, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. *Annals of Oncology*. 2014;435–441.
6. Omazic Brigitta, Remberger Mats, Barkholt Lisbeth, et al. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. *Biol Blood Marrow Transplant*. 2016;676-681.
7. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Nov 2015;21(11):1863-1869.
8. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
9. Peinemann F, Enk H, Smith LA. Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas. *Cochrane Database Syst Rev*. Apr 2017;4.